论文部分内容阅读
目的:探讨重组人促红细胞生成素治疗慢性肾脏病贫血的疗效和安全性。方法:慢性肾脏病贫血80例患者随机分为两组各40例,两组均行常规血液透析与补血治疗,治疗组在此基础上加用重组人促红细胞生成素皮下注射治疗。8周后评价疗效和安全性。结果:治疗组总有效率为95.0%,高于对照组的总有效率80.0%(P<0.05)。治疗后两组血红蛋白和红细胞压积均较治疗前显著升高(P<0.05),治疗组显著高于对照组(P<0.05)。两组均未发生药品不良反应。结论:重组人促红细胞生成素辅助治疗慢性肾脏病贫血能有效提高疗效,改善贫血状况,安全性好。
Objective: To investigate the efficacy and safety of recombinant human erythropoietin in the treatment of anemia of chronic kidney disease. Methods: Eighty patients with anemia of chronic kidney disease were randomly divided into two groups of 40 cases. Both groups were treated with routine hemodialysis and blood enrichment. The treatment group was treated with recombinant human erythropoietin subcutaneously. Efficacy and safety were evaluated after 8 weeks. Results: The total effective rate was 95.0% in the treatment group and 80.0% in the control group (P <0.05). After treatment, hemoglobin and hematocrit in both groups were significantly higher than those before treatment (P <0.05), and were significantly higher in the treatment group than those in the control group (P <0.05). No adverse drug reactions occurred in both groups. Conclusion: Recombinant human erythropoietin adjuvant treatment of anemia of chronic kidney disease can effectively improve the efficacy, improve anemia, and good safety.